Sarcoidosis-Associated Pulmonary Hypertension and Lung Transplantation for Sarcoidosis

 

 Buy Article Permissions and Reprints

Abstract

Pulmonary hypertension (PH) is a significant complication of sarcoidosis, occurring in approximately 6 to > 20% of cases, and markedly increases mortality among these patients. The clinician should exercise a high index of suspicion for sarcoidosis-associated PH (SAPH) given the nonspecific symptomatology and the limitations of echocardiography in this patient population. The pathophysiology of PH in sarcoidosis is complex and multifactorial. Importantly, there are inherent differences in the pathogenesis of SAPH compared with idiopathic pulmonary arterial hypertension, making the optimal management of SAPH controversial. In this article, we review the epidemiology, diagnosis, prognosis, and treatment considerations for SAPH. Lung transplantation (LT) is a viable therapeutic option for sarcoid patients with severe pulmonary fibrocystic sarcoidosis or SAPH refractory to medical therapy. We discuss the role for LT in patients with sarcoidosis, review the global experience with LT in this population, and discuss indications and contraindications to LT.

• References

• 1 Cordova FC, D'Alonzo G. Sarcoidosis-associated pulmonary hypertension. Curr Opin Pulm Med 2013; 19 (5) 531-537
  CrossrefPubMedGoogle Scholar
• 2 Battesti JP, Georges R, Basset F, Saumon G. Chronic cor pulmonale in pulmonary sarcoidosis. Thorax 1978; 33 (1) 76-84
  CrossrefPubMedGoogle Scholar
• 3 Głuskowski J, Hawryłkiewicz I, Zych D, Wojtczak A, Zieliński J. Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Respiration 1984; 46 (1) 26-32
  CrossrefPubMedGoogle Scholar
• 4 Handa T, Nagai S, Miki S , et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129 (5) 1246-1252
  CrossrefPubMedGoogle Scholar
• 5 Milman N, Burton CM, Iversen M, Videbaek R, Jensen CV, Carlsen J. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?. J Heart Lung Transplant 2008; 27 (3) 329-334
  CrossrefPubMedGoogle Scholar
• 6 Mitchell DN, Scadding JG. Sarcoidosis. Am Rev Respir Dis 1974; 110 (6) 774-802
  PubMedGoogle Scholar
• 7 Rizzato G, Pezzano A, Sala G , et al. Right heart impairment in sarcoidosis: haemodynamic and echocardiographic study. Eur J Respir Dis 1983; 64 (2) 121-128
  PubMedGoogle Scholar
• 8 Shorr AF, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002; 122 (1) 233-238
  CrossrefPubMedGoogle Scholar
• 9 Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128 (3) 1483-1489
  CrossrefPubMedGoogle Scholar
• 10 Nunes H, Humbert M, Capron F , et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61 (1) 68-74
  CrossrefPubMedGoogle Scholar
• 11 Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124 (3) 922-928
  CrossrefPubMedGoogle Scholar
• 12 Shah L. Lung transplantation in sarcoidosis. Semin Respir Crit Care Med 2007; 28 (1) 134-140
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Galiè N, Hoeper MM, Humbert M , et al; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30 (20) 2493-2537
  CrossrefPubMedGoogle Scholar
• 14 Lahm T, Chakinala MM. World Health Organization group 5 pulmonary hypertension. Clin Chest Med 2013; 34 (4) 753-778
  CrossrefPubMedGoogle Scholar
• 15 Preston IR, Klinger JR, Landzberg MJ, Houtchens J, Nelson D, Hill NS. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001; 120 (3) 866-872
  CrossrefPubMedGoogle Scholar
• 16 Maimon N, Salz L, Shershevsky Y, Matveychuk A, Guber A, Shitrit D. Sarcoidosis-associated pulmonary hypertension in patients with near-normal lung function. Int J Tuberc Lung Dis 2013; 17 (3) 406-411
  CrossrefPubMedGoogle Scholar
• 17 Takemura T, Matsui Y, Oritsu M , et al. Pulmonary vascular involvement in sarcoidosis: granulomatous angiitis and microangiopathy in transbronchial lung biopsies. Virchows Arch A Pathol Anat Histopathol 1991; 418 (4) 361-368
  CrossrefPubMedGoogle Scholar
• 18 Takemura T, Matsui Y, Saiki S, Mikami R. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum Pathol 1992; 23 (11) 1216-1223
  CrossrefPubMedGoogle Scholar
• 19 Rosen Y, Moon S, Huang CT, Gourin A, Lyons HA. Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med 1977; 101 (4) 170-174
  PubMedGoogle Scholar
• 20 Carrington CB. Structure and function in sarcoidosis. Ann N Y Acad Sci 1976; 278: 265-283
  CrossrefPubMedGoogle Scholar
• 21 Rosen Y. Pathology of sarcoidosis. Semin Respir Crit Care Med 2007; 28 (1) 36-52
  Article in Thieme ConnectPubMedGoogle Scholar
• 22 Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005; 25 (5) 783-788
  CrossrefPubMedGoogle Scholar
• 23 Damuth TE, Bower JS, Cho K, Dantzker DR. Major pulmonary artery stenosis causing pulmonary hypertension in sarcoidosis. Chest 1980; 78 (6) 888-891
  CrossrefPubMedGoogle Scholar
• 24 Gaston B, Drazen JM, Loscalzo J, Stamler JS. The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med 1994; 149 (2, Pt 1) 538-551
  CrossrefPubMedGoogle Scholar
• 25 Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333 (4) 214-221
  CrossrefPubMedGoogle Scholar
• 26 Milman N, Svendsen CB, Iversen M, Videbaek R, Carlsen J. Sarcoidosis-associated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil. Clin Respir J 2009; 3 (4) 207-213
  CrossrefPubMedGoogle Scholar
• 27 Galié N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61 (2) 227-237
  CrossrefPubMedGoogle Scholar
• 28 Giaid A, Yanagisawa M, Langleben D , et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328 (24) 1732-1739
  CrossrefPubMedGoogle Scholar
• 29 Sofia M, Mormile M, Faraone S, Alifano M, Carratù P, Carratù L. Endothelin-1 excretion in urine in active pulmonary sarcoidosis and in other interstitial lung diseases. Sarcoidosis 1995; 12 (2) 118-123
  PubMedGoogle Scholar
• 30 Reichenberger F, Schauer J, Kellner K, Sack U, Stiehl P, Winkler J. Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung 2001; 179 (3) 163-174
  CrossrefPubMedGoogle Scholar
• 31 Terashita K, Kato S, Sata M, Inoue S, Nakamura H, Tomoike H. Increased endothelin-1 levels of BAL fluid in patients with pulmonary sarcoidosis. Respirology 2006; 11 (2) 145-151
  CrossrefPubMedGoogle Scholar
• 32 Letizia C, Danese A, Reale MG , et al. Plasma levels of endothelin-1 increase in patients with sarcoidosis and fall after disease remission. Panminerva Med 2001; 43 (4) 257-261
  PubMedGoogle Scholar
• 33 Barnett CF, Bonura EJ, Nathan SD , et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest 2009; 135 (6) 1455-1461
  CrossrefPubMedGoogle Scholar
• 34 Baughman RP, Engel PJ, Meyer CA, Barrett AB, Lower EE. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (2) 108-116
  PubMedGoogle Scholar
• 35 Foley RJ, Metersky ML. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan. Respiration 2008; 75 (2) 211-214
  CrossrefPubMedGoogle Scholar
• 36 Hoffstein V, Ranganathan N, Mullen JB. Sarcoidosis simulating pulmonary veno-occlusive disease. Am Rev Respir Dis 1986; 134 (4) 809-811
  PubMedGoogle Scholar
• 37 Jones RM, Dawson A, Jenkins GH, Nicholson AG, Hansell DM, Harrison NK. Sarcoidosis-related pulmonary veno-occlusive disease presenting with recurrent haemoptysis. Eur Respir J 2009; 34 (2) 517-520
  CrossrefPubMedGoogle Scholar
• 38 Portier F, Lerebours-Pigeonniere G, Thiberville L , et al. [Sarcoidosis simulating a pulmonary veno-occlusive disease]. Rev Mal Respir 1991; 8 (1) 101-102
  PubMedGoogle Scholar
• 39 Wagenvoort CA, Wagenvoort N. The pathology of pulmonary veno-occlusive disease. Virchows Arch A Pathol Anat Histol 1974; 364 (1) 69-79
  CrossrefPubMedGoogle Scholar
• 40 Montani D, O'Callaghan DS, Savale L , et al. Pulmonary veno-occlusive disease: recent progress and current challenges. Respir Med 2010; 104 (Suppl. 01) S23-S32
  CrossrefPubMedGoogle Scholar
• 41 Roberts WC, McAllister Jr HA, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med 1977; 63 (1) 86-108
  CrossrefPubMedGoogle Scholar
• 42 Mehta D, Lubitz SA, Frankel Z , et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 2008; 133 (6) 1426-1435
  CrossrefPubMedGoogle Scholar
• 43 Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 1995; 119 (2) 167-172
  PubMedGoogle Scholar
• 44 Iwai K, Sekiguti M, Hosoda Y , et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 1994; 11 (1) 26-31
  PubMedGoogle Scholar
• 45 Simonneau G, Robbins IM, Beghetti M , et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (1, Suppl): S43-S54
  CrossrefPubMedGoogle Scholar
• 46 Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008; 32 (2) 296-302
  CrossrefPubMedGoogle Scholar
• 47 Arcasoy SM, Christie JD, Pochettino A , et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest 2001; 120 (3) 873-880
  CrossrefPubMedGoogle Scholar
• 48 Saggar R, Saggar R, Aboulhosn J, Belperio JA, Zisman DA, Lynch III JP. Diagnosis and hemodynamic assessment of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009; 30 (4) 399-410
  Article in Thieme ConnectPubMedGoogle Scholar
• 49 Hoeper MM, Lee SH, Voswinckel R , et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48 (12) 2546-2552
  CrossrefPubMedGoogle Scholar
• 50 Devaraj A, Wells AU, Meister MG, Corte TJ, Hansell DM. The effect of diffuse pulmonary fibrosis on the reliability of CT signs of pulmonary hypertension. Radiology 2008; 249 (3) 1042-1049
  CrossrefPubMedGoogle Scholar
• 51 Emirgil C, Sobol BJ, Herbert WH, Trout K. The lesser circulation in pulmonary fibrosis secondary to sarcoidosis and its relationship to respiratory function. Chest 1971; 60 (4) 371-378
  CrossrefPubMedGoogle Scholar
• 52 Arcasoy SM, Christie JD, Ferrari VA , et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167 (5) 735-740
  CrossrefPubMedGoogle Scholar
• 53 Nathan SD, Shlobin OA, Barnett SD , et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2008; 102 (9) 1305-1310
  CrossrefPubMedGoogle Scholar
• 54 Zisman DA, Ross DJ, Belperio JA , et al. Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2007; 101 (10) 2153-2159
  CrossrefPubMedGoogle Scholar
• 55 Rich JD, Shah SJ, Swamy RS, Kamp A, Rich S. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest 2011; 139 (5) 988-993
  CrossrefPubMedGoogle Scholar
• 56 Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132 (1) 207-213
  CrossrefPubMedGoogle Scholar
• 57 Macfarlane JT. Prognosis in sarcoidosis. Br Med J (Clin Res Ed) 1984; 288 (6430) 1557-1558
  CrossrefPubMedGoogle Scholar
• 58 Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357 (21) 2153-2165
  CrossrefPubMedGoogle Scholar
• 59 Lynch III JP, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. Clin Chest Med 1997; 18 (4) 755-785
  CrossrefPubMedGoogle Scholar
• 60 Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160 (2) 736-755
  CrossrefPubMedGoogle Scholar
• 61 Baughman RP. Pulmonary sarcoidosis. Clin Chest Med 2004; 25 (3) 521-530 , vi
  CrossrefPubMedGoogle Scholar
• 62 Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc 2013; 10 (4) 362-370
  CrossrefPubMedGoogle Scholar
• 63 Lynch III JP, Ma YL, Koss MN, White ES. Pulmonary sarcoidosis. Semin Respir Crit Care Med 2007; 28 (1) 53-74
  Article in Thieme ConnectPubMedGoogle Scholar
• 64 Gluskowski J, Hawrylkiewicz I, Zych D, Zieliński J. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J 1990; 3 (4) 403-407
  PubMedGoogle Scholar
• 65 Pitsiou G, Papakosta D, Bouros D. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Respiration 2011; 82 (3) 294-304
  CrossrefPubMedGoogle Scholar
• 66 Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007; 132 (3) 998-1006
  CrossrefPubMedGoogle Scholar
• 67 Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130 (5) 1481-1488
  CrossrefPubMedGoogle Scholar
• 68 Olschewski H, Ghofrani HA, Walmrath D , et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160 (2) 600-607
  CrossrefPubMedGoogle Scholar
• 69 Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir Rev 2009; 18 (111) 29-34
  PubMedGoogle Scholar
• 70 Baughman RP, Judson MA, Lower EE , et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26 (2) 110-120
  PubMedGoogle Scholar
• 71 Baughman RP. Pulmonary hypertension associated with sarcoidosis. Arthritis Res Ther 2007; 9 (Suppl. 02) S8
  CrossrefPubMedGoogle Scholar
• 72 Sharma S, Kashour T, Philipp R. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Tex Heart Inst J 2005; 32 (3) 405-410
  PubMedGoogle Scholar
• 73 Baughman RP, Culver DA, Cordova FC , et al. Bosentan for sarcoidosis associated pulmonary hypertension: A double-blind placebo controlled randomized trial. Chest 2013; (Oct) 31
  PubMedGoogle Scholar
• 74 Judson MA, Highland KB, Kwon S , et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28 (2) 139-145
  PubMedGoogle Scholar
• 75 Dobarro D, Schreiber BE, Handler C, Beynon H, Denton CP, Coghlan JG. Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. Am J Cardiol 2013; 111 (2) 278-285
  CrossrefPubMedGoogle Scholar
• 76 Walker S, Mikhail G, Banner N , et al. Medium term results of lung transplantation for end stage pulmonary sarcoidosis. Thorax 1998; 53 (4) 281-284
  CrossrefPubMedGoogle Scholar
• 77 Yusen RD, Christie JD, Edwards LB , et al; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: thirtieth adult lung and heart-lung transplant report—2013; focus theme: age. J Heart Lung Transplant 2013; 32 (10) 965-978
  CrossrefPubMedGoogle Scholar
• 78 Orens JB, Estenne M, Arcasoy S , et al; Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25 (7) 745-755
  CrossrefPubMedGoogle Scholar
• 79 Baughman RP, Winget DB, Bowen EH, Lower EE. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14 (2) 154-158
  PubMedGoogle Scholar
• 80 Wollschlager C, Khan F. Aspergillomas complicating sarcoidosis. A prospective study in 100 patients. Chest 1984; 86 (4) 585-588
  CrossrefPubMedGoogle Scholar
• 81 Patterson GA. Clinical-pathologic conference in general thoracic surgery: bilateral lung transplantation for sarcoidosis with aspergilloma. J Thorac Cardiovasc Surg 2002; 124 (1) 171-175
  CrossrefPubMedGoogle Scholar
• 82 Hadjiliadis D, Sporn TA, Perfect JR, Tapson VF, Davis RD, Palmer SM. Outcome of lung transplantation in patients with mycetomas. Chest 2002; 121 (1) 128-134
  CrossrefPubMedGoogle Scholar
• 83 Shorr AF, Helman DL, Davies DB, Nathan SD. Sarcoidosis, race, and short-term outcomes following lung transplantation. Chest 2004; 125 (3) 990-996
  CrossrefPubMedGoogle Scholar
• 84 Young CJ, Gaston RS. African Americans and renal transplantation: disproportionate need, limited access, and impaired outcomes. Am J Med Sci 2002; 323 (2) 94-99
  CrossrefPubMedGoogle Scholar
• 85 Nair S, Eustace J, Thuluvath PJ. Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet 2002; 359 (9303) 287-293
  CrossrefPubMedGoogle Scholar
• 86 Collins J, Hartman MJ, Warner TF , et al. Frequency and CT findings of recurrent disease after lung transplantation. Radiology 2001; 219 (2) 503-509
  CrossrefPubMedGoogle Scholar
• 87 Martinez FJ, Orens JB, Deeb M, Brunsting LA, Flint A, Lynch III JP. Recurrence of sarcoidosis following bilateral allogeneic lung transplantation. Chest 1994; 106 (5) 1597-1599
  CrossrefPubMedGoogle Scholar
• 88 Bjørtuft O, Foerster A, Boe J, Geiran O. Single lung transplantation as treatment for end-stage pulmonary sarcoidosis: recurrence of sarcoidosis in two different lung allografts in one patient. J Heart Lung Transplant 1994; 13 (1, Pt 1) 24-29
  PubMedGoogle Scholar